戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 urosteroids, allopregnanolone and tetrahydro-deoxycorticosterone.
2 one metabolites migrated at the same rate as deoxycorticosterone.
3 rences in glucocorticoids, cortisone, and 11-deoxycorticosterone.
4               After 7 days of treatment with deoxycorticosterone (2 mg/day), an increased number of H
5 ase-3 (NOS3) expression in rats treated with deoxycorticosterone acetate (DOCA) and high salt.
6  (SD), spontaneously hypertensive (SHR), and deoxycorticosterone acetate (DOCA) hypertensive single c
7 sverse aortic constriction (TAC) surgery and deoxycorticosterone acetate (DOCA) pellet implantation.
8 )-Nitro-L-arginine Methyl Ester (L-NAME) and Deoxycorticosterone Acetate (DOCA) rat models.
9  1% saline to drink) or by implantation of a deoxycorticosterone acetate (DOCA) tablet (1% saline to
10                                Arteries from deoxycorticosterone acetate (DOCA)-salt and N(omega)-nit
11 ertensive mice with kidney injury induced by deoxycorticosterone acetate (DOCA)-salt compared to the
12                                              Deoxycorticosterone acetate (DOCA)-salt hypertension is
13                                  We utilized deoxycorticosterone acetate (DOCA)-salt hypertension mod
14 ugmented by increased endothelin-1 (ET-1) in deoxycorticosterone acetate (DOCA)-salt hypertension, a
15 scular superoxide level is also increased in deoxycorticosterone acetate (DOCA)-salt hypertension, wh
16 ound that CXCL16 is induced in the kidney in deoxycorticosterone acetate (DOCA)-salt hypertension.
17  ChR2-expressing mice that were subjected to deoxycorticosterone acetate (DOCA)-salt hypertension; ho
18                                       In the deoxycorticosterone acetate (DOCA)-salt model of hyperte
19 CT7263 (BFM) would attenuate hypertension in deoxycorticosterone acetate (DOCA)-salt rats, a renin-in
20 th CTLA4-Ig reduced both angiotensin II- and deoxycorticosterone acetate (DOCA)-salt-induced hyperten
21 hat are administered the aldosterone-mimetic deoxycorticosterone acetate (DOCA).
22  study, we investigated the role of CXCR6 in deoxycorticosterone acetate (DOCA)/salt-induced inflamma
23 studied 2 weeks later) mice without and with deoxycorticosterone acetate administration, all in the s
24 ension driven by combined uninephrectomy and deoxycorticosterone acetate administration.
25 sfunction mouse models were studied: (1) TAC-deoxycorticosterone acetate and (2) Lepr(db/db).
26                                    Exogenous deoxycorticosterone acetate and deletion of the P2Y(2) r
27 vels in thoracic aortas when challenged with deoxycorticosterone acetate and high-salt diet (DOCA-sal
28 er the induction of severe hypertension with deoxycorticosterone acetate and salt, proteinuria, impai
29           Compared with sham mice, sham plus deoxycorticosterone acetate mice had mild hypertrophy wi
30 on mice, transverse aortic constriction plus deoxycorticosterone acetate mice had similar left ventri
31 lar matrix proteins in LVs of uninephrectomy/deoxycorticosterone acetate mice, which correlated with
32  relaxation was unimpaired in uninephrectomy/deoxycorticosterone acetate mice.
33 d in intact cardiomyocytes isolated from TAC-deoxycorticosterone acetate mice.
34 rs left ventricular chamber stiffness in TAC-deoxycorticosterone acetate mice.
35 taneous implantation of a controlled-release deoxycorticosterone acetate pellet, and given 1% saline
36 s after uninephrectomy and implantation with deoxycorticosterone acetate pellets, when DD was clearly
37  inflammatory pathways in the development of deoxycorticosterone acetate salt hypertension.
38 ed CKD, unilateral ureteric obstruction, and deoxycorticosterone acetate salt unilateral nephrectomy
39 d inflammasome activation in mouse models of deoxycorticosterone acetate salt-induced hypertension as
40 ion per se were studied in uninephrectomized deoxycorticosterone acetate salt-treated rats, where the
41 ust sodium appetite (e.g., sodium depletion, deoxycorticosterone acetate) decrease lateral hypothalam
42 ropriate for salt status, mineralocorticoid (deoxycorticosterone acetate) excess causes hypertrophy,
43 e further subjected to the nephrectomy/DOCA (deoxycorticosterone acetate) model of diastolic dysfunct
44 ed left ventricular chamber stiffness in TAC-deoxycorticosterone acetate, but not in Lepr(db/db) mice
45  sodium channel inhibitor, in a rat model of deoxycorticosterone acetate, unilateral nephrectomy, and
46  prevented decreases in the ECu50 induced by deoxycorticosterone acetate-no salt treatment.
47                       In aortas of mice with deoxycorticosterone acetate-salt (DOCA-salt) hypertensio
48 se in RMR in response to a high-fat diet and deoxycorticosterone acetate-salt (DOCA-salt) treatments,
49 pes in the brain, ADAM17 upregulation during deoxycorticosterone acetate-salt hypertension occurs sel
50 y and attenuates Ang II (angiotensin II) and deoxycorticosterone acetate-salt induced hypertension.
51         To test this hypothesis, we used the deoxycorticosterone acetate-salt model of neurogenic hyp
52 ebrospinal fluid of nontransgenic mice after deoxycorticosterone acetate-salt treatment and were acco
53                                              Deoxycorticosterone acetate-salt treatment in nontransge
54 have shown that stimuli like angiotensin II, deoxycorticosterone acetate-salt, and excessive catechol
55 tory factor, in angiotensin II- (ANGII-) and deoxycorticosterone acetate-salt-induced (DOCA-salt-indu
56 +) intake regardless of the presence of high deoxycorticosterone acetate.
57 cement therapy with either corticosterone or deoxycorticosterone acetate.
58      Administration of the mineralocorticoid deoxycorticosterone-acetate (DOCA) in combination with h
59 1-hydroxylase, converting progesterone to 11-deoxycorticosterone and 17alpha-hydroxyprogesterone (17a
60 ntration promote binding of the substrate 11-deoxycorticosterone and the inhibitor osilodrostat (LCI6
61 o develop an in vitro CYP11B2 assay using 11-deoxycorticosterone as a substrate.
62                                 Substrate 11-deoxycorticosterone binds CYP11B2 primarily through a br
63 asured activities, aldosterone, cortisol, 11-deoxycorticosterone, corticosterone, 11-deoxcortisol, pr
64      3alpha,5alpha-THDOC is synthesized from deoxycorticosterone (DOC) by metabolism in adrenals and
65 ceptor-modulating neurosteroids derived from deoxycorticosterone (DOC) play a role in stress-related
66 one oxetanone (Dex-Ox), progesterone (Prog), deoxycorticosterone (DOC), and RU486.
67 corticosteroids, 11-deoxycortisol (S) and 11-deoxycorticosterone (DOC).
68               Male rats pretreated with both deoxycorticosterone (DOC; a synthetic precursor of aldos
69 metry further identified as major species of deoxycorticosterone metabolites 3beta,6alpha,21-trihydro
70 apid transformation of both progesterone and deoxycorticosterone; one of the progesterone metabolites
71                            OMCD tubules from deoxycorticosterone pivalate (DOCP)-treated rats were pe
72 h fat diet (HFD) and the hypertensive agent, deoxycorticosterone pivalate (DOCP).
73 ns of aldosterone, corticosterone, cortisol, deoxycorticosterone, pregnenolone, and progesterone in b
74 ynthesized in the brain from progesterone or deoxycorticosterone, respectively, by the sequential act
75 salt-sensitive hypertension: high salt and a deoxycorticosterone salt diet.
76  cells was initiated with the addition of 11-deoxycorticosterone, the immediate substrate of aldoster
77 11B2 catalyzes aldosterone formation from 11-deoxycorticosterone through three distinct oxidation ste
78 ven access to concentrated saline (3% NaCl), deoxycorticosterone-treated rats drank eight times more